Open access
Aug 2026
Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort.
MMUD with PTCy-based GVHD prophylaxis and RIC/NMA conditioning was safe and effective to facilitate HCT and outcomes were similar in the expansion cohort that enrolled from a greater number of centers.
Brian C. Shaffer, M. A. Al Malki, Antonio M. Jimenez et al.
· American journal of hematolo... · 0 citations